GlassScriptPhysician profile
Andrea A Harper
NPI 1700853892
$8,265.75
in general payments reported to CMS, 2019-2025
23 companies · $2,494 in 2025
The $2,494 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $629 · 2020: $378 · 2021: $552 · 2022: $983 · 2023: $1,197 · 2024: $2,033 · 2025: $2,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,711 · Education: $12.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,711.02 |
| Education | $12.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $2,096.67 | 2019-2025 | Idosetr, Idose, Istent Infinite |
| Sight Sciences, INC. | $1,252.89 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Abbvie INC. | $736.11 | 2023-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $500.34 | 2019-2024 | Tecnis Iol, Catalys System, Tecnis Iol |
| Sun Pharmaceutical Industries INC. | $482.04 | 2019-2024 | Cequa |
| Bausch & Lomb Americas INC. | $449.04 | 2022-2025 | Envista Mx60 Iol, Vyzulta, Xiidra |
| Alcon Vision LLC | $447.60 | 2020-2025 | Hydrus Microstent, Clareon, Tryptyr |
| New World Medical,INC. | $386.66 | 2021-2023 | |
| Biotissue Holdings INC. | $230.33 | 2023-2025 | |
| Allergan, INC. | $223.75 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $215.52 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $187.61 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $140.51 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $134.92 | 2021 | |
| Astellas Pharma US INC | $132.43 | 2025 | Izervay |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $129.69 | 2021-2022 | |
| Harrow Eye, LLC | $120.96 | 2025 | Vevye |
| Apellis Pharmaceuticals, INC. | $120.29 | 2025 | Syfovre |
| Dompe US, INC. | $107.63 | 2023 | Oxervate |
| Genentech USA, INC. | $69.21 | 2019 | |
| Mallinckrodt Hospital Products INC. | $55.18 | 2024-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $26.97 | 2019-2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Harper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.